Chiusura precedente | 0,1480 |
Aperto | 0,1530 |
Denaro | 0,1450 x 0 |
Lettera | 0,1780 x 0 |
Min-Max giorno | 0,1400 - 0,1550 |
Intervallo di 52 settimane | 0,0700 - 0,1980 |
Volume | |
Media Volume | 1.418 |
Capitalizzazione | N/D |
Beta (5 anni mensile) | N/D |
Rapporto PE (ttm) | N/D |
EPS (ttm) | N/D |
Prossima data utili | 09 mag 2024 - 13 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Receives first purchase order from Gensco® PharmaSAINT LAURENT, Quebec, Sept. 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has received the first purchase order (“PO”) for RIZAFILM®1 from its commercial partner in the United States, Gensco Pharma (“Gensco®”). The PO triggers an upfront order deposit payment. A pre-specified milestone payment to IntelGenx from Gensco® is also payable upon transfer of NDA. Both payments w
SAINT LAURENT, Quebec, Sept. 19, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today provided a regulatory update on Buprenorphine Buccal Film, for which an abbreviated new drug application (“ANDA”) has been filed with the U.S. Food and Drug Administration (“FDA” or the “Agency”) by its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”). As previously announced, Xiromed received a Complete Response Letter (“CR
SAINT LAURENT, Quebec, Aug. 31, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) announces the closing of the first tranche of a non-brokered private placement (the “Offering”) of units (“Units”) from atai Life Sciences AG (“atai”) for aggregate gross proceeds of approximately US$3 million, including US$750,000 to be received by the Company pursuant to the Subsequent atai Subscription (as defined below) once the Shareholder Approvals (as